World's Best Scientists 2026 revealed!

Anthony H. Goldstone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anthony H. Goldstone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Anthony H. Goldstone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anthony H. Goldstone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Anthony H. Goldstone is affiliated with University College London in the United Kingdom. Their research primarily focuses on various aspects of medicine, with notable contributions in hematology, oncology, public health, environmental and occupational health, pediatrics, perinatology, and child health.

The scientist's body of work spans several main topics, including:

  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Childhood Cancer Survivors' Quality of Life
  • CAR-T cell therapy research
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Viral Infectious Diseases and Gene Expression in Insects

Key recent papers authored or co-authored by Anthony H. Goldstone include:

  • Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL, 2021, published in Blood
  • Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years, 2024, Blood Cancer Journal
  • At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial, 2020, British Journal of Haematology
  • Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL, 2020, British Journal of Haematology
  • Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells, 2023, Blood

Frequent co-authors collaborating with Anthony H. Goldstone include:

  • Elisabeth Paietta
  • Kathryn G. Roberts
  • Georgina Buck
  • Cheryl L. Willman
  • Hillard M. Lazarus

Their publications are mainly featured in the following journals:

  • Blood
  • British Journal of Haematology
  • Blood Cancer Journal

This researcher's work covers intersecting fields of hematology, oncology, and pediatric health, often focusing on the diagnosis, treatment, and outcomes related to leukemias and lymphomas. They have contributed to understanding risk assessment in leukemia as well as to the development and evaluation of hematopoietic stem cell transplantation and CAR-T cell therapy for blood cancers.

Best Publications

  • The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

    Panagiotis D. Kottaridis;Rosemary E. Gale;Marion E. Frew;Georgina Harrison

  • Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

    David Grimwade;Robert K. Hills;Anthony V. Moorman;Helen Walker

  • Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

    Norbert Schmitz;Beate Pfistner;Michael Sextro;Markus Sieber

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

    Adele K. Fielding;Susan M. Richards;Rajesh Chopra;Hillard M. Lazarus

  • Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

    Alan Kenneth Burnett;Anthony H. Goldstone;Richard M. F. Stevens;Ian M. Hann

  • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment†‡

    Alan Kenneth Burnett;Donald Milligan;Archie G. Prentice;Anthony H. Goldstone

  • Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

    Alan Kenneth Burnett;Robert Kerrin Hills;Donald Milligan;Lars Kjeldsen

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.

    Keith Wheatley;Alan Kenneth Burnett;Anthony H. Goldstone;Richard G. Gray

  • Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

    Anthony H. Goldstone;Alan Kenneth Burnett;Keith Wheatley;Alastair G. Smith

  • In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

    Panagiotis D Kottaridis;Donald W Milligan;Rajesh Chopra;Ronjon Chakraverty

  • Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid: Result of the Randomized MRC Trial

    Alan K. Burnett;David Grimwade;Ellen Solomon;Keith Wheatley

  • Hepatitis B transmission from contaminated cryopreservation tank

    R.S Tedder;M.A Zuckerman;N.S Brink;A.H Goldstone

  • Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

    Stephen P. Robinson;Anthony H. Goldstone;Stephen Mackinnon;Angelo Carella

  • The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

    Alan Kenneth Burnett;Keith Wheatley;Anthony H. Goldstone;Richard F. Stevens

  • Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers

    Richard S. Maser;Bhudipa Choudhury;Peter J. Campbell;Bin Feng

  • Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10)

    Ian M. Hann;Richard F. Stevens;Anthony H. Goldstone;John K.H. Rees

  • T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

    David I. Marks;Elisabeth M. Paietta;Anthony V. Moorman;Susan M. Richards

  • High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

    Suparno Chakrabarti;Stephen Mackinnon;Rajesh Chopra;Panagiotis D Kottaridis

Frequent Co-Authors

Martin S. Tallman
Martin S. Tallman Northwestern University
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Jacob M. Rowe
Jacob M. Rowe Technion – Israel Institute of Technology
David C. Linch
David C. Linch University College London
David I. Marks
David I. Marks University Hospitals Bristol NHS Foundation Trust
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Anthony V. Moorman
Anthony V. Moorman Newcastle University
Karl S. Peggs
Karl S. Peggs University College London
Donald Milligan
Donald Milligan University of Birmingham
Gordon W. Dewald
Gordon W. Dewald Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a medical career but seeking flexible or alternative pathways, there are many online degrees and programs to explore. The healthcare field is evolving, making it easier to study nursing or pursue advanced roles online.

Start your journey by comparing the cheapest rn to bsn degree options. These programs are designed for current RNs who want to earn a bachelor’s degree, boost their qualifications, and unlock more job opportunities at a lower cost.

For non-nurses interested in rapidly launching a nursing career, there are direct entry nurse practitioner programs for non-nurses online. These programs can lead to advanced practice roles, even if your undergraduate background is outside of nursing.

For those aiming for teaching or leadership roles, consider the online phd nursing programs, which offer flexibility and affordability for working professionals.

Not sure where to start? Explore nursing schools with high acceptance rates to find accessible entry points for your studies. Whichever route you choose, online healthcare education offers convenience and a path to rewarding careers.

Best Scientists Citing Anthony H. Goldstone

Trending Scientists